Farther Finance Advisors LLC Grows Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Farther Finance Advisors LLC increased its holdings in Eli Lilly and Company by 31.8%, owning 23,495 shares valued at approximately $18.3 million.
• Analysts have mixed ratings on Eli Lilly, with one report suggesting a strong-buy rating, while others have downgraded it, leaving the consensus rating at Moderate Buy.
• Eli Lilly reported earnings of $6.31 per share for the last quarter, exceeding expectations, and showing a 37.6% year-over-year revenue growth with total revenue of $15.56 billion.

Farther Finance Advisors LLC grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 31.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,495 shares of the company's stock after buying an additional 5,670 shares during the period. Farther Finance Advisors LLC's holdings in Eli Lilly and Company were worth $18,315,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in LLY. PNC Financial Services Group Inc. raised its holdings in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC increased its holdings in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after buying an additional 14,852,076 shares in the last quarter. Nuveen LLC purchased a new position in Eli Lilly and Company in the first quarter valued at $4,613,912,000. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Finally, Cohen Investment Advisors LLC increased its holdings in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after buying an additional 773,947 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LLY shares. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Cantor Fitzgerald cut their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Finally, Berenberg Bank reissued a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director J Erik Fyrwald purchased 1,565 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $8.79 during trading on Tuesday, reaching $746.16. The company's stock had a trading volume of 1,480,140 shares, compared to its average volume of 4,082,746. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $939.30. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business's fifty day moving average price is $737.49 and its 200-day moving average price is $769.01. The firm has a market cap of $706.21 billion, a price-to-earnings ratio of 48.77, a P/E/G ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the business posted $3.92 earnings per share. The business's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.